Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri

Francois Lebreton; Brendan W. Corey; Christi L. McElheny; Alina Iovleva; Lan Preston; Katie R. Margulieux; Robert J. Cybulski; Patrick Mc Gann; Yohei Doi; Jason W. Bennett

doi:10.1128/AAC.00150-21

Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri

Francois Lebreton, Brendan W. Corey, Christi L. McElheny, Alina Iovleva, Lan Preston, Katie R. Margulieux, Robert J. Cybulski, Patrick Mc Gann, Yohei Doi, Jason W. Bennett

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

KPC-82 is a KPC-2 variant identified in a carbapenem-nonsusceptible Citrobacter koseri that confers high-level resistance to ceftazidime-avibactam. Genomic analysis revealed that bla_KPC-82 is carried by a chromosomally integrated Tn4401 transposon (disrupting porin gene phoE) and evolved by a 6-nucleotide tandem repeat duplication causing a two-amino-acid insertion (Ser-Asp) within the Ala₂₆₇-Ser₂₇₅ loop. Similar to related KPC variants, KPC-82 showed decreased carbapenemase activity when expressed in a heterologous background and remained susceptible to carbapenem/b-lactamase inhibitor combinations.

Original language	English
Article number	e00150-21
Journal	Antimicrobial agents and chemotherapy
Volume	65
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00150-21
Publication status	Published - 07-2021
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/AAC.00150-21

Cite this

Lebreton, F., Corey, B. W., McElheny, C. L., Iovleva, A., Preston, L., Margulieux, K. R., Cybulski, R. J., Gann, P. M., Doi, Y., & Bennett, J. W. (2021). Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri. Antimicrobial agents and chemotherapy, 65(7), Article e00150-21. https://doi.org/10.1128/AAC.00150-21

@article{430bbd60f7484bab928d2a3d53a0d53d,

title = "Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri",

abstract = "KPC-82 is a KPC-2 variant identified in a carbapenem-nonsusceptible Citrobacter koseri that confers high-level resistance to ceftazidime-avibactam. Genomic analysis revealed that blaKPC-82 is carried by a chromosomally integrated Tn4401 transposon (disrupting porin gene phoE) and evolved by a 6-nucleotide tandem repeat duplication causing a two-amino-acid insertion (Ser-Asp) within the Ala267-Ser275 loop. Similar to related KPC variants, KPC-82 showed decreased carbapenemase activity when expressed in a heterologous background and remained susceptible to carbapenem/b-lactamase inhibitor combinations.",

keywords = "CRE, Carbapenems, Ceftazidime-avibactam, Citrobacter koseri, KPC",

author = "Francois Lebreton and Corey, {Brendan W.} and McElheny, {Christi L.} and Alina Iovleva and Lan Preston and Margulieux, {Katie R.} and Cybulski, {Robert J.} and Gann, {Patrick Mc} and Yohei Doi and Bennett, {Jason W.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Lebreton et al",

year = "2021",

month = jul,

doi = "10.1128/AAC.00150-21",

language = "English",

volume = "65",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

Lebreton, F, Corey, BW, McElheny, CL, Iovleva, A, Preston, L, Margulieux, KR, Cybulski, RJ, Gann, PM, Doi, Y & Bennett, JW 2021, 'Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri', Antimicrobial agents and chemotherapy, vol. 65, no. 7, e00150-21. https://doi.org/10.1128/AAC.00150-21

Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri. / Lebreton, Francois; Corey, Brendan W.; McElheny, Christi L. et al.
In: Antimicrobial agents and chemotherapy, Vol. 65, No. 7, e00150-21, 07.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri

AU - Lebreton, Francois

AU - Corey, Brendan W.

AU - McElheny, Christi L.

AU - Iovleva, Alina

AU - Preston, Lan

AU - Margulieux, Katie R.

AU - Cybulski, Robert J.

AU - Gann, Patrick Mc

AU - Doi, Yohei

AU - Bennett, Jason W.

PY - 2021/7

Y1 - 2021/7

N2 - KPC-82 is a KPC-2 variant identified in a carbapenem-nonsusceptible Citrobacter koseri that confers high-level resistance to ceftazidime-avibactam. Genomic analysis revealed that blaKPC-82 is carried by a chromosomally integrated Tn4401 transposon (disrupting porin gene phoE) and evolved by a 6-nucleotide tandem repeat duplication causing a two-amino-acid insertion (Ser-Asp) within the Ala267-Ser275 loop. Similar to related KPC variants, KPC-82 showed decreased carbapenemase activity when expressed in a heterologous background and remained susceptible to carbapenem/b-lactamase inhibitor combinations.

AB - KPC-82 is a KPC-2 variant identified in a carbapenem-nonsusceptible Citrobacter koseri that confers high-level resistance to ceftazidime-avibactam. Genomic analysis revealed that blaKPC-82 is carried by a chromosomally integrated Tn4401 transposon (disrupting porin gene phoE) and evolved by a 6-nucleotide tandem repeat duplication causing a two-amino-acid insertion (Ser-Asp) within the Ala267-Ser275 loop. Similar to related KPC variants, KPC-82 showed decreased carbapenemase activity when expressed in a heterologous background and remained susceptible to carbapenem/b-lactamase inhibitor combinations.

KW - CRE

KW - Carbapenems

KW - Ceftazidime-avibactam

KW - Citrobacter koseri

KW - KPC

UR - http://www.scopus.com/inward/record.url?scp=85108274280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108274280&partnerID=8YFLogxK

U2 - 10.1128/AAC.00150-21

DO - 10.1128/AAC.00150-21

M3 - Article

C2 - 33972237

AN - SCOPUS:85108274280

SN - 0066-4804

VL - 65

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 7

M1 - e00150-21

ER -

Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of citrobacter koseri

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this